Choosing the Right Biotech Exit Strategy

Update: 2019-09-24

Description

In this episode of BDO’s Health & Life Sciences Rx Podcast, BDO’s Todd Berry sits down with leaders from Universal Cells, Fortress Biotech, and McDermott Will & Emery to discuss how leaders in biotech can assess the current M&A and IPO landscape to choose the right exit strategy for their organization.

Comments

In Channel

Knowing When to Call It Quits in Drug Development and Healthcare Innovations

2020-05-2234:28

Choosing the Right Biotech Exit Strategy

2019-09-2442:15

Unleashing Nurse-Led Innovation

2019-05-0131:58

Adapting to Changing Market Winds: Healthcare REITS and Private Equity

2019-04-1037:06

Preparing for the Future of Elder Care

2019-03-0652:31

Global Conversations on Elder Care

2018-12-1330:15

Checking Healthcare's Pulse

2018-10-0823:22

Finding the Right Dose of Portfolio Risk

2018-05-1423:56

Adjusting to Disruption: The “New Normal” in Healthcare

2018-04-1801:07:36

The Future of Digital Health: Fireside Chat with Dr. Karen DeSalvo

2018-03-2727:41

00:00

Choosing the Right Biotech Exit Strategy

#box-pro-ellipsis-176504804413873{-webkit-line-clamp:2;}Choosing the Right Biotech Exit Strategy

Choosing the Right Biotech Exit Strategy

Choosing the Right Biotech Exit Strategy